Prelude Therapeutics Incorporated (PRLD) 10-Year Financial Performance & Capital Metrics

PRLD • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutPrelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.Show more

Revenue $7M
EBITDA -$138M -5.2%
Net Income -$127M -4.4%
EPS (Diluted) -1.68 +16.8%
Gross Margin 100%
EBITDA Margin -1970.6%
Operating Margin -1995.91%
Net Margin -1816.76%
ROE -69.01% -22.5%
ROIC -57.31% -14.2%
Debt/Equity 0.14 +92.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 25.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM250%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.01%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.88%

ROCE

10Y Avg-80.52%

5Y Avg-54.99%

3Y Avg-59.35%

Latest-68.87%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	7M
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	149K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-149K	0	0	0	0	0	7M
Gross Margin %	-	-	-	-	-	-	1%
Gross Profit Growth %	-	1%	-	-	-	-	-
Operating Expenses+	14.97M	28.11M	58.76M	113.73M	123.54M	132.28M	146.71M
OpEx % of Revenue	-	-	-	-	-	-	20.96%
Selling, General & Admin	2.35M	3.83M	10.59M	26.96M	30.65M	28.88M	28.72M
SG&A % of Revenue	-	-	-	-	-	-	4.1%
Research & Development	12.62M	24.28M	48.18M	86.78M	92.89M	103.39M	118M
R&D % of Revenue	-	-	-	-	-	-	16.86%
Other Operating Expenses	0	0	0	0	0	-1	0
Operating Income+	-14.97M	-28.11M	-58.76M	-113.73M	-123.54M	-132.28M	-139.71M
Operating Margin %	-	-	-	-	-	-	-19.96%
Operating Income Growth %	-	-0.88%	-1.09%	-0.94%	-0.09%	-0.07%	-0.06%
EBITDA+	-14.83M	-27.73M	-58.22M	-112.82M	-122.22M	-131.11M	-137.94M
EBITDA Margin %	-	-	-	-	-	-	-19.71%
EBITDA Growth %	-	-0.87%	-1.1%	-0.94%	-0.08%	-0.07%	-0.05%
D&A (Non-Cash Add-back)	149K	382K	542K	915K	1.32M	1.17M	1.77M
EBIT	-14.97M	-28.11M	-58.76M	-113.73M	-123.54M	-132.28M	-139.71M
Net Interest Income+	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	295K	539K	1.83M	2.04M	8.1M	10.44M	12.54M
Pretax Income+	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Pretax Margin %	-	-	-	-	-	-	-18.17%
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Net Margin %	-	-	-	-	-	-	-18.17%
Net Income Growth %	-	-0.88%	-1.06%	-0.96%	-0.03%	-0.06%	-0.04%
Net Income (Continuing)	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-9.31	-0.85	-1.30	-2.33	-2.27	-2.02	-1.68
EPS Growth %	-	0.91%	-0.53%	-0.79%	0.03%	0.11%	0.17%
EPS (Basic)	-9.31	-0.85	-1.30	-2.33	-2.27	-2.02	-1.68
Diluted Shares Outstanding	1.58M	32.4M	43.71M	47.6M	47.37M	60.36M	75.81M
Basic Shares Outstanding	1.58M	32.4M	43.71M	47.6M	47.37M	60.36M	75.81M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	15.6M	20.22M	220.81M	295.12M	204.38M	235.59M	135.9M
Cash & Short-Term Investments	15.6M	18.88M	218.31M	291.23M	201.73M	232.94M	133.61M
Cash Only	15.6M	18.88M	218.31M	31.83M	30.61M	25.29M	12.47M
Short-Term Investments	0	0	0	259.4M	171.12M	207.64M	121.14M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	2.5M	0	2.65M	2.65M	2.28M
Total Non-Current Assets+	811K	1.65M	2.78M	9.98M	16.12M	42.08M	39.62M
Property, Plant & Equipment	811K	1.65M	2.48M	5.64M	6.7M	37.74M	35.47M
Fixed Asset Turnover	-	-	-	-	-	-	0.20x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	301K	4.35M	9.42M	4.34M	4.15M
Total Assets+	16.41M	21.87M	223.59M	305.1M	220.5M	277.67M	175.51M
Asset Turnover	-	-	-	-	-	-	0.04x
Asset Growth %	-	0.33%	9.22%	0.36%	-0.28%	0.26%	-0.37%
Total Current Liabilities+	2.45M	4.83M	11.38M	19.2M	21.7M	21.83M	25.64M
Accounts Payable	1.36M	1.97M	3.92M	7.84M	6.78M	4.58M	7.73M
Days Payables Outstanding	3.34K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	1.63M	420K	5.01M	6.21M	6.61M	9.79M
Current Ratio	6.37x	4.18x	19.41x	15.37x	9.42x	10.79x	5.30x
Quick Ratio	6.37x	4.18x	19.41x	15.37x	9.42x	10.79x	5.30x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	36.65M	66.45M	32K	0	3.36M	18.75M	18.41M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	15.41M	15.32M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	36.65M	66.45M	32K	0	3.36M	3.34M	3.09M
Total Liabilities	39.1M	71.28M	11.41M	19.2M	25.06M	40.58M	44.06M
Total Debt+	0	258K	0	1.74M	1.83M	16.89M	18.02M
Net Debt	-15.6M	-18.62M	-218.31M	-30.09M	-28.77M	-8.4M	5.55M
Debt / Equity	-	-	-	0.01x	0.01x	0.07x	0.14x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-22.69M	-49.41M	212.18M	285.9M	195.44M	237.09M	131.46M
Equity Growth %	-	-1.18%	5.29%	0.35%	-0.32%	0.21%	-0.45%
Book Value per Share	-14.40	-1.52	4.85	6.01	4.13	3.93	1.73
Total Shareholders' Equity	-22.69M	-49.41M	212.18M	285.9M	195.44M	237.09M	131.46M
Common Stock	0	0	4K	5K	5K	5K	5K
Retained Earnings	-22.93M	-50.5M	-107.43M	-219.12M	-334.56M	-456.39M	-583.56M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-191K	0	-223.59M	-711K	-1.69M	223K	35K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.95M	-25.66M	-46.18M	-83.53M	-83.73M	-107.06M	-102.89M
Operating CF Margin %	-	-	-	-	-	-	-14.7%
Operating CF Growth %	-	-0.98%	-0.8%	-0.81%	-0%	-0.28%	0.04%
Net Income	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Depreciation & Amortization	149K	382K	542K	915K	1.32M	1.17M	1.77M
Stock-Based Compensation	180K	846K	5.58M	20.93M	25.14M	25.62M	21.34M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	15K	10K	11K	2.69M	4.31M	-1.54M	-3.05M
Working Capital Changes	1.38M	667K	4.62M	3.63M	932K	-10.48M	4.22M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	721K	546K	1.16M	3.9M	-347K	-2.27M	3.31M
Cash from Investing+	-529K	-780K	-621K	-263.8M	81.69M	-34.65M	90.19M
Capital Expenditures	-529K	-780K	-621K	-2.32M	-3.02M	-3.51M	-764K
CapEx % of Revenue	-	-	-	-	-	-	0.11%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	17.94M	29.73M	246.23M	164.9M	815K	136.4M	-120K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	5K	88K	3.47M	815K	664K	-54K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-13.48M	-26.45M	-46.8M	-85.85M	-86.75M	-110.58M	-103.65M
FCF Margin %	-	-	-	-	-	-	-14.81%
FCF Growth %	-	-0.96%	-0.77%	-0.83%	-0.01%	-0.27%	0.06%
FCF per Share	-8.55	-0.82	-1.07	-1.80	-1.83	-1.83	-1.37
FCF Conversion (FCF/Net Income)	0.88x	0.93x	0.81x	0.75x	0.73x	0.88x	0.81x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-69.95%	-44.85%	-47.97%	-56.34%	-69.01%
Return on Invested Capital (ROIC)	-	-	-	-68.33%	-43.86%	-50.19%	-57.31%
Gross Margin	-	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-	-1816.76%
Debt / Equity	-	-	-	0.01x	0.01x	0.07x	0.14x
FCF Conversion	0.88x	0.93x	0.81x	0.75x	0.73x	0.88x	0.81x

Frequently Asked Questions

Growth & Financials

Prelude Therapeutics Incorporated (PRLD) reported $10.5M in revenue for fiscal year 2024.

Prelude Therapeutics Incorporated (PRLD) grew revenue by 0.0% over the past year. Growth has been modest.

Prelude Therapeutics Incorporated (PRLD) reported a net loss of $111.8M for fiscal year 2024.

Dividend & Returns

Prelude Therapeutics Incorporated (PRLD) has a return on equity (ROE) of -69.0%. Negative ROE indicates the company is unprofitable.

Prelude Therapeutics Incorporated (PRLD) had negative free cash flow of $100.3M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener

US Stock Screener

...

Prelude Therapeutics Incorporated (PRLD) 10-Year Financial Performance & Capital Metrics

PRLD • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $7M
EBITDA -$138M -5.2%
Net Income -$127M -4.4%
EPS (Diluted) -1.68 +16.8%
Gross Margin 100%
EBITDA Margin -1970.6%
Operating Margin -1995.91%
Net Margin -1816.76%
ROE -69.01% -22.5%
ROIC -57.31% -14.2%
Debt/Equity 0.14 +92.5%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 95 (top 5%)
✓Trading at only 1.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 3/9
✗Negative free cash flow
✗Shares diluted 25.6% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM250%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM15.01%

EPS CAGR

10Y-

5Y-

3Y-

TTM17.88%

ROCE

10Y Avg-80.52%

5Y Avg-54.99%

3Y Avg-59.35%

Latest-68.87%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	7M
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	149K	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-149K	0	0	0	0	0	7M
Gross Margin %	-	-	-	-	-	-	1%
Gross Profit Growth %	-	1%	-	-	-	-	-
Operating Expenses+	14.97M	28.11M	58.76M	113.73M	123.54M	132.28M	146.71M
OpEx % of Revenue	-	-	-	-	-	-	20.96%
Selling, General & Admin	2.35M	3.83M	10.59M	26.96M	30.65M	28.88M	28.72M
SG&A % of Revenue	-	-	-	-	-	-	4.1%
Research & Development	12.62M	24.28M	48.18M	86.78M	92.89M	103.39M	118M
R&D % of Revenue	-	-	-	-	-	-	16.86%
Other Operating Expenses	0	0	0	0	0	-1	0
Operating Income+	-14.97M	-28.11M	-58.76M	-113.73M	-123.54M	-132.28M	-139.71M
Operating Margin %	-	-	-	-	-	-	-19.96%
Operating Income Growth %	-	-0.88%	-1.09%	-0.94%	-0.09%	-0.07%	-0.06%
EBITDA+	-14.83M	-27.73M	-58.22M	-112.82M	-122.22M	-131.11M	-137.94M
EBITDA Margin %	-	-	-	-	-	-	-19.71%
EBITDA Growth %	-	-0.87%	-1.1%	-0.94%	-0.08%	-0.07%	-0.05%
D&A (Non-Cash Add-back)	149K	382K	542K	915K	1.32M	1.17M	1.77M
EBIT	-14.97M	-28.11M	-58.76M	-113.73M	-123.54M	-132.28M	-139.71M
Net Interest Income+	0	0	0	0	0	0	0
Interest Income	0	0	0	0	0	0	0
Interest Expense	0	0	0	0	0	0	0
Other Income/Expense	295K	539K	1.83M	2.04M	8.1M	10.44M	12.54M
Pretax Income+	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Pretax Margin %	-	-	-	-	-	-	-18.17%
Income Tax+	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Net Margin %	-	-	-	-	-	-	-18.17%
Net Income Growth %	-	-0.88%	-1.06%	-0.96%	-0.03%	-0.06%	-0.04%
Net Income (Continuing)	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-9.31	-0.85	-1.30	-2.33	-2.27	-2.02	-1.68
EPS Growth %	-	0.91%	-0.53%	-0.79%	0.03%	0.11%	0.17%
EPS (Basic)	-9.31	-0.85	-1.30	-2.33	-2.27	-2.02	-1.68
Diluted Shares Outstanding	1.58M	32.4M	43.71M	47.6M	47.37M	60.36M	75.81M
Basic Shares Outstanding	1.58M	32.4M	43.71M	47.6M	47.37M	60.36M	75.81M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	15.6M	20.22M	220.81M	295.12M	204.38M	235.59M	135.9M
Cash & Short-Term Investments	15.6M	18.88M	218.31M	291.23M	201.73M	232.94M	133.61M
Cash Only	15.6M	18.88M	218.31M	31.83M	30.61M	25.29M	12.47M
Short-Term Investments	0	0	0	259.4M	171.12M	207.64M	121.14M
Accounts Receivable	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	2.5M	0	2.65M	2.65M	2.28M
Total Non-Current Assets+	811K	1.65M	2.78M	9.98M	16.12M	42.08M	39.62M
Property, Plant & Equipment	811K	1.65M	2.48M	5.64M	6.7M	37.74M	35.47M
Fixed Asset Turnover	-	-	-	-	-	-	0.20x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	301K	4.35M	9.42M	4.34M	4.15M
Total Assets+	16.41M	21.87M	223.59M	305.1M	220.5M	277.67M	175.51M
Asset Turnover	-	-	-	-	-	-	0.04x
Asset Growth %	-	0.33%	9.22%	0.36%	-0.28%	0.26%	-0.37%
Total Current Liabilities+	2.45M	4.83M	11.38M	19.2M	21.7M	21.83M	25.64M
Accounts Payable	1.36M	1.97M	3.92M	7.84M	6.78M	4.58M	7.73M
Days Payables Outstanding	3.34K	-	-	-	-	-	-
Short-Term Debt	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	0	1.63M	420K	5.01M	6.21M	6.61M	9.79M
Current Ratio	6.37x	4.18x	19.41x	15.37x	9.42x	10.79x	5.30x
Quick Ratio	6.37x	4.18x	19.41x	15.37x	9.42x	10.79x	5.30x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	36.65M	66.45M	32K	0	3.36M	18.75M	18.41M
Long-Term Debt	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	15.41M	15.32M
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	36.65M	66.45M	32K	0	3.36M	3.34M	3.09M
Total Liabilities	39.1M	71.28M	11.41M	19.2M	25.06M	40.58M	44.06M
Total Debt+	0	258K	0	1.74M	1.83M	16.89M	18.02M
Net Debt	-15.6M	-18.62M	-218.31M	-30.09M	-28.77M	-8.4M	5.55M
Debt / Equity	-	-	-	0.01x	0.01x	0.07x	0.14x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-
Total Equity+	-22.69M	-49.41M	212.18M	285.9M	195.44M	237.09M	131.46M
Equity Growth %	-	-1.18%	5.29%	0.35%	-0.32%	0.21%	-0.45%
Book Value per Share	-14.40	-1.52	4.85	6.01	4.13	3.93	1.73
Total Shareholders' Equity	-22.69M	-49.41M	212.18M	285.9M	195.44M	237.09M	131.46M
Common Stock	0	0	4K	5K	5K	5K	5K
Retained Earnings	-22.93M	-50.5M	-107.43M	-219.12M	-334.56M	-456.39M	-583.56M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-191K	0	-223.59M	-711K	-1.69M	223K	35K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-12.95M	-25.66M	-46.18M	-83.53M	-83.73M	-107.06M	-102.89M
Operating CF Margin %	-	-	-	-	-	-	-14.7%
Operating CF Growth %	-	-0.98%	-0.8%	-0.81%	-0%	-0.28%	0.04%
Net Income	-14.68M	-27.57M	-56.93M	-111.69M	-115.44M	-121.83M	-127.17M
Depreciation & Amortization	149K	382K	542K	915K	1.32M	1.17M	1.77M
Stock-Based Compensation	180K	846K	5.58M	20.93M	25.14M	25.62M	21.34M
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	15K	10K	11K	2.69M	4.31M	-1.54M	-3.05M
Working Capital Changes	1.38M	667K	4.62M	3.63M	932K	-10.48M	4.22M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	721K	546K	1.16M	3.9M	-347K	-2.27M	3.31M
Cash from Investing+	-529K	-780K	-621K	-263.8M	81.69M	-34.65M	90.19M
Capital Expenditures	-529K	-780K	-621K	-2.32M	-3.02M	-3.51M	-764K
CapEx % of Revenue	-	-	-	-	-	-	0.11%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	0
Cash from Financing+	17.94M	29.73M	246.23M	164.9M	815K	136.4M	-120K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	5K	88K	3.47M	815K	664K	-54K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-13.48M	-26.45M	-46.8M	-85.85M	-86.75M	-110.58M	-103.65M
FCF Margin %	-	-	-	-	-	-	-14.81%
FCF Growth %	-	-0.96%	-0.77%	-0.83%	-0.01%	-0.27%	0.06%
FCF per Share	-8.55	-0.82	-1.07	-1.80	-1.83	-1.83	-1.37
FCF Conversion (FCF/Net Income)	0.88x	0.93x	0.81x	0.75x	0.73x	0.88x	0.81x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-69.95%	-44.85%	-47.97%	-56.34%	-69.01%
Return on Invested Capital (ROIC)	-	-	-	-68.33%	-43.86%	-50.19%	-57.31%
Gross Margin	-	-	-	-	-	-	100%
Net Margin	-	-	-	-	-	-	-1816.76%
Debt / Equity	-	-	-	0.01x	0.01x	0.07x	0.14x
FCF Conversion	0.88x	0.93x	0.81x	0.75x	0.73x	0.88x	0.81x

Frequently Asked Questions

Growth & Financials

Prelude Therapeutics Incorporated (PRLD) reported $10.5M in revenue for fiscal year 2024.

Prelude Therapeutics Incorporated (PRLD) grew revenue by 0.0% over the past year. Growth has been modest.

Prelude Therapeutics Incorporated (PRLD) reported a net loss of $111.8M for fiscal year 2024.

Dividend & Returns

Prelude Therapeutics Incorporated (PRLD) has a return on equity (ROE) of -69.0%. Negative ROE indicates the company is unprofitable.

Prelude Therapeutics Incorporated (PRLD) had negative free cash flow of $100.3M in fiscal year 2024, likely due to heavy capital investments.